Study of the concordance between p16 immunohistochemistry and HPV-PCR genotyping for the viral diagnosis of oropharyngeal squamous cell carcinoma

European Annals of Otorhinolaryngology, Head and Neck Diseases

Volumn 132, Issue 3, 2015, Pages 135-139

  Fonmarty, D ^a   Cherriere S ^a   Fleury, H ^a   Eimer, S ^a   Majoufre Lefebvre, C ^a   Castetbon, V ^a   De Mones E ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

HPV; Oropharyngeal cancer; P16; PCR

Indexed keywords

PROTEIN P16; P16 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; VIRUS DNA;

ADULT; ALCOHOL ABUSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAW TUMOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CANCER; PHARYNX TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SMOKING; TONGUE TUMOR; TONSIL TUMOR; TUMOR BIOPSY; TUMOR DIFFERENTIATION; WART VIRUS; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; COMPLICATION; EVALUATION STUDY; FRANCE; GENETICS; GENOTYPE; HUMAN PAPILLOMAVIRUS DNA TEST; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; PREDICTIVE VALUE; PREVALENCE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VIROLOGY;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; FRANCE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84930931947     PISSN: 18797296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anorl.2015.01.003     Document Type: Article

References (17)

1. Syrjanen K, Syrjanen S, Lamberg M, et al. Morphological and immunohisto-chemical evidence suggesting human papillomavirus (HPV) involvement inoral squamous cell carcinogenesis. Int J Oral Surg 1983;12:418-24.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papilloma virus andrising oropharyngeal cancer incidence in the United States. J Clin Oncol2011;29:4294-301.
3. Lacau St Guily J, Jacquard AC, Pretet JL, et al. Human papillomavirus genotypedistribution in oropharynx and oral cavity cancer in France-The EDiTH VIstudy. J Clin Virol 2011;51:100-4.
4. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival ofpatients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
5. Petrelli F, Sarti E, Barni S. Predictive value of human papillomavirus in orop-haryngeal carcinoma treated with radiotherapy: an updated systematic reviewand meta-analysis of 30 trials. Head Neck 2014;36:750-9.
6. Mirghani H, Amen F, Moreau F, et al. Human papilloma virus testing in orop-haryngeal squamous cell carcinoma: what the clinician should know. OralOncol 2014;50:1-9.
7. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection ofhuman papillomavirus in paraffin-embedded head and neck cancer specimen.Int J Cancer 2007;121:2465-72.
8. Jung AC, Briolat J, Million R, et al. Biological and clinical relevance of transcrip-tionally active human papillomavirus (HPV) infection in oropharynx squamouscell carcinoma. Int J Cancer 2010;126:1882-94.
9. Schache AG, Liloglou T, Risk JM, et al. Evaluation of human papil-loma virus diagnostic testing in oropharyngeal squamous cell carcinoma:sensitivity, specificity and prognostic discrimination. Clin Cancer Res 2011;17:6262-71.
10. Thomas J, Primeaux T. Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associatedhead and neck squamous cell carcinoma? Ann Diagn Pathol 2012;16:91-9.
11. Lewis JS, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squa-mous cell carcinoma: an entity with a favorable prognosis regardless of tumorHPV status. Am J Surg Pathol 2010;34:1088-96.
12. Kreimer AR, Clifford GM, Boyle P, et al. Human Papillomavirus types in headand neck squamous cell carcinomas worldwide: a systematic review. CancerEpidemiol Biomarkers Prev 2005;14:467-75.
13. Ribeiro KB, Levi JE, Pawlita M, et al. Low human papillomavirus prevalencein head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol 2011;40:489-502.
14. Dayyani F, Etzel CJ, Liu M, et al. Meta-analysis of the impact of human papillo-mavirus (HPV) on cancer risk and overall survival in head and neck squamouscell carcinomas (HNSCC). Head Neck Oncol 2010;2:15.
15. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relationto smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers Cancer 2007;110:1429-35.
16. Begum S, Cao D, Gillison M, et al. Tissue distribution oh human papillo-mavirus 16 DNA integration in patients with tonsillar carcinoma. Clin CancerRes 2005;11:5694-9.
17. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival ratebetween smokers and nonsmokers with HPV-16-associated tonsillar carcino-mas. Int J Cancer 2008;122:2656-64.